作者: A. A. Lashkov , N. E. Zhukhlistova , T. A. Seregina , A. G. Gabdulkhakov , A. M. Mikhailov
DOI: 10.1134/S1063774511040122
关键词:
摘要: The activation of xenobiotics often causes malignant tumor cells to resist chemotherapeutic treatment. Uridine phosphorylase is the key enzyme pyrimidine metabolism and catalyzes reversible phosphorylation uridine with formation uracil ribose-1-phosphate. High-selectivity anticancer agents based on inhibitors are promising for treating both oncological infection diseases. New medicinal preparations can be predicted rationally developed only basis detailed biomedical, structural, functional knowledge about biomacromolecular target enzyme-drug complex.